Thalidomide-O-C2-acid

• CAT Number: I029899
• CAS Number: 2369068-42-6
• Molecular Formula: C16H14N2O7
• Molecular Weight: 346.29
• Purity: ≥95%
• Synonyms: 3-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxypropanoic acid
• InChI: InChI=1S/C16H14N2O7/c19-11-5-4-9(14(22)17-11)18-15(23)8-2-1-3-10(13(8)16(18)24)25-7-6-12(20)21/h1-3,9H,4-7H2,(H,20,21)(H,17,19,22)
• InChIKey: JDORXWYUBMQFIZ-UHFFFAOYSA-N
• SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)OCCC(=O)O

Thalidomide-O-C2-acid (Cat No.: I029899) is a thalidomide-based derivative containing a two-carbon alkyl linker terminating in a carboxylic acid group. The thalidomide core binds to cereblon (CRBN), an E3 ubiquitin ligase substrate receptor, enabling recruitment of target proteins for ubiquitination and proteasomal degradation in PROTAC (proteolysis-targeting chimera) designs. The terminal carboxylic acid serves as a reactive handle for conjugation to various ligands or linkers. Thalidomide-O-C2-acid is widely used in targeted protein degradation research for developing therapeutics against cancer, immune disorders, and neurodegenerative diseases.

Reference

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11.
[Content Brief]

[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-1008.
[Content Brief]